These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 7136723)

  • 1. Pharmacokinetics of hydroflumethiazide during repeated administration in congestive heart failure.
    Brørs O
    Acta Pharmacol Toxicol (Copenh); 1982 Sep; 51(3):177-81. PubMed ID: 7136723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Distribution of elimination of hydroflumethiazide in man.
    Brørs O; Jacobsen S
    Eur J Clin Pharmacol; 1979 Sep; 16(2):125-31. PubMed ID: 499309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of repeated doses of hydroflumethiazide on renal excretion of electrolytes and uric acid in healthy subjects.
    Brørs O; Jacobsen S; Foss OP; Aakvaag A
    Acta Pharmacol Toxicol (Copenh); 1981 Feb; 48(2):145-50. PubMed ID: 7257825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of hydroflumethiazide in congestive heart failure: renal electrolyte excretion related to urinary thiazide excretion and aldosterone.
    Brørs O; Enger E; Jacobsen S; Aakvaag A; Foss OP
    Acta Pharmacol Toxicol (Copenh); 1981 Nov; 49(5):399-406. PubMed ID: 7345881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Excretion of hydroflumethiazide in bile and urine of man.
    Brørs O; Haffner JF; Jacobsen S
    Eur J Clin Pharmacol; 1979 May; 15(4):287-9. PubMed ID: 477714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of orally administered hydroflumethiazide in man.
    Yakatan GJ; Smith RB; Frome EL; Doluisio JT
    J Clin Pharmacol; 1977 Jan; 17(1):37-47. PubMed ID: 833338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of hydroflumethiazide during repeated oral administration to healthy subjects.
    Brørs O; Jacobsen S
    Eur J Clin Pharmacol; 1979 May; 15(4):281-6. PubMed ID: 477713
    [No Abstract]   [Full Text] [Related]  

  • 8. Pharmacokinetics of a single oral dose of hydroflumethiazide in health and in cardiac failure.-.
    Brørs O; Jacobsen S; Arnesen E
    Eur J Clin Pharmacol; 1978 Nov; 14(1):29-37. PubMed ID: 729604
    [No Abstract]   [Full Text] [Related]  

  • 9. Fluorometric determination of hydroflumethiazide in human plasma and urine after its oral administration.
    Brors O; Jacobsen S; Arnesen E
    Eur J Clin Pharmacol; 1977 Jan; 11(2):149-54. PubMed ID: 837968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism of flecainide.
    Conard GJ; Ober RE
    Am J Cardiol; 1984 Feb; 53(5):41B-51B. PubMed ID: 6364769
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In chronic heart failure with marked fluid retention, the i.v. high doses of loop diuretic are a predictor of aggravated renal dysfunction, especially in the set of heart failure with normal or only mildly impaired left ventricular systolic function.
    De Vecchis R; Ciccarelli A; Ariano C; Cioppa C; Giasi A; Pucciarelli A; Cantatrione S
    Minerva Cardioangiol; 2011 Dec; 59(6):543-54. PubMed ID: 21330961
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of ranitidine in patients with renal failure.
    Garg DC; Baltodano N; Jallad NS; Perez G; Oster JR; Eshelman FN; Weidler DJ
    J Clin Pharmacol; 1986 Apr; 26(4):286-91. PubMed ID: 3700684
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical pharmacokinetics of prazosin.
    Jaillon P
    Clin Pharmacokinet; 1980; 5(4):365-76. PubMed ID: 6994981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of terazosin.
    Sonders RC
    Am J Med; 1986 May; 80(5B):20-4. PubMed ID: 2872802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydralazine and furosemide kinetics.
    Nomura A; Yasuda H; Katoh K; Akimoto T; Miyazaki K; Arita T
    Clin Pharmacol Ther; 1982 Sep; 32(3):303-6. PubMed ID: 7105621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dose- and time-dependent binding and kinetics of pindolol in patients with congestive heart failure.
    Lima JJ; Binkley PF; Johnson J; Leier CV
    J Clin Pharmacol; 1986 Apr; 26(4):253-7. PubMed ID: 3700683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Kinetics, dynamics, and bioavailability of bumetanide in healthy subjects and patients with congestive heart failure.
    Cook JA; Smith DE; Cornish LA; Tankanow RM; Nicklas JM; Hyneck ML
    Clin Pharmacol Ther; 1988 Nov; 44(5):487-500. PubMed ID: 3180632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interaction of hydroflumethiazide and 2,4-disulfamyl-5-trifluoromethylaniline with cyclic AMP phosphodiesterase and carbonic anhydrase.
    Brørs O; Braut GS; Braut S; Jacobsen S
    Acta Pharmacol Toxicol (Copenh); 1982 Oct; 51(4):273-7. PubMed ID: 6295063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of renal failure, rheumatoid arthritis and old age on the pharmacokinetics of diflunisal.
    Erikson LO; Wåhlin-Boll E; Odar-Cederlöf I; Lindholm L; Melander A
    Eur J Clin Pharmacol; 1989; 36(2):165-74. PubMed ID: 2721541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acebutolol pharmacokinetics in renal failure.
    Smith RS; Warren DJ; Renwick AG; George CF
    Br J Clin Pharmacol; 1983 Sep; 16(3):253-8. PubMed ID: 6626416
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.